查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年單克隆抗體市場預測 - 按來源類型、生產類型、適應症、途徑、配銷通路、用途、最終用戶和地區進行的全球分析
市場調查報告書
商品編碼
1339962

到 2030 年單克隆抗體市場預測 - 按來源類型、生產類型、適應症、途徑、配銷通路、用途、最終用戶和地區進行的全球分析

Monoclonal Antibodies Market Forecasts to 2030 - Global Analysis By Source Type, Production Type, Indication, Route of Administration, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC的數據，2023年全球單克隆抗體市場規模為2306億美元，預計到2030年將達到5915億美元，預測期內年複合成長率為14.4%。

單克隆抗體 (mAb) 是一種能夠與特定細胞類型結合的蛋白質。這些是相同的免疫球蛋白，可識別抗原上的特定結合位點，並由單個 B 細胞產生。由於單克隆抗體對不同表位具有選擇性，因此它們擴大用於各種疾病的治療和診斷。單克隆抗體目前廣泛用於治療多種疾病，包括癌症、心血管疾病、自身免疫性疾病、血液疾病和感染疾病等。

據世界衛生組織 (WHO) 稱，2020 年全球約有 1000 萬人將死於癌症。這相當於每年所有癌症死亡人數的三分之一。

市場動態：

促進因素

  • 對個人化醫療的青睞日益成長。
  • 治療性抗體的研究和開發正在為標靶治療鋪平道路，並增加對個人化醫療的需求。由於單克隆抗體用於治療癌症，因此與傳統化療相比，這些治療方法不太可能引起副作用。個體化癌症治療和單克隆抗體減少副作用預計將促進新興市場的開拓。

抑制要素

  • 嚴重的法規問題。
  • 有關藥物核准和藥物測試的嚴格法規要求阻礙了市場擴張。此外，許多國家禁止在獲得必要的批准之前對藥物進行人體測試。曾經無法治癒的疾病現在可以通過商業治療方法治愈，這為創新藥物引入市場鋪平了道路。與這些藥物相關的眾多法規合規性阻礙了市場擴張。

機會：

  • 癌症罹患率增加
  • 影響市場成長率的主要要素之一是癌症罹患率的上升。隨著單克隆抗體的全球市場迅速擴大，已開發國家擴大使用單克隆抗體來治療多種腫瘤。罕見疾病和慢性感染疾病的患病率迅速增加，以及大量單克隆抗體被推薦用於癌症治療方案，為收入擴張提供了市場潛力。

威脅

  • 單克隆抗體高成本。
  • 由於單克隆抗體的生產成本昂貴，因此僅在已開發國家使用，而在新興國家或較貧窮國家不使用。高昂的藥品成本可能會阻礙貧窮國家許多患者群體的吸收並限制他們獲得藥品。高開發成本和隨後的價格上漲可能會限制市場擴張。

新冠肺炎 (COVID-19) 影響：

  • 此次疫情對經濟產生了三個主要影響。它直接影響了藥品的需求和生產，擾亂了分配系統，並對企業和金融市場產生了財務影響。單克隆抗體市場受益於這一影響，因為單克隆抗體可以預防和治療早期感染疾病。許多公司正在使用單克隆抗體來開發針對新型冠狀病毒的有效疫苗。研究人員通過危機識別得到了政府機構的支持。
  • 腫瘤學領域預計在預測期內規模最大
  • 由於癌症患病率不斷上升，預計癌症行業在預測期內將達到最高水平。這種擴張是由於治療各種癌症時對單克隆抗體的需求不斷增加。癌症患者對單克隆抗體需求量大的主要原因之一是其在癌症治療中的有效性提高，且副作用極小或無副作用。
  • 醫院藥房業務預計在預測期內年複合成長率最高
  • 預計醫院藥房行業在預測期內的年複合成長率最高。這是由於癌症、類風濕性關節炎等許多慢性疾病的患病率上升導致住院患者人數增加。由於現代醫療保健服務的普及，酒店藥房市場收入正在增加。這些藥店出售各種產品和藥品，可以輕鬆購買各種藥品。

佔比最大的地區

由於主要企業的存在和大量的產品核可，預計北美在預測期內將佔據最大的市場佔有率。該地區對單克隆抗體的需求是由於人們對有效疾病治療產品的接受度不斷提高而推動的。此外，公司研發支出的增加和政府對癌症研究的資助正在推動創新單克隆抗體治療的發展。

複合年複合成長率最高的地區：

由於可支配收入的增加和對醫療保健的興趣日益濃厚，預計亞太地區在預測期內將保持最高的年複合成長率。預計人口中癌症和其他慢性病患病率增加的主要原因是加工食品消費量增加、吸煙率增加和煙草使用增加。此外，不斷成長的老年人口可能會對不久的將來的銷售產生積極影響。

免費客製化服務：

訂閱此報告的客戶將收到以下免費客製化選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（注：基於可行性檢查）
  • 競爭標杆管理
    • 根據產品系列、地域分佈和戰略聯盟對主要企業進行基準測試

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 資料挖掘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 假設

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 用途分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球單克隆抗體市場：按來源類型

  • 人性化
  • 奇美拉
  • 小鼠或大鼠
  • 男人
  • 其他產地類型

第6章 全球單克隆抗體市場：按生產類型

  • In Vitro
  • In Vivo

第7章 全球單克隆抗體市場：按適應症分類

  • 感染疾病
  • 炎症性疾病
  • 癌症
    • 肺癌
    • 結直腸癌
    • 卵巢癌
    • 乳腺癌
  • 自身免疫性疾病
  • 其他適應症

第8章 全球單克隆抗體市場：按給藥途徑

  • 玻璃體內
  • 皮下的
  • 靜脈

第9章 全球單克隆抗體市場：按配銷通路分類

  • 網上藥房
  • 醫院藥房
  • 零售藥房

第10章 全球單克隆抗體市場：按用途

  • 感染疾病
  • 神經系統疾病
  • 自身免疫性疾病
  • 腫瘤學
  • 其他用途

第11章全球單克隆抗體市場：按最終用戶分類

  • 專業中心
  • 醫院
  • 調查機構
  • 其他最終用戶

第12章全球單克隆抗體市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第13章進展

  • 契約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第14章公司簡介

  • Johnson & Johnson Services, Inc.
  • Viatris Inc.
  • Abbott Laboratories
  • Eli Lilly And Company
  • Bristol-Myers Squibb
  • Biogen Inc.
  • Merck & Co., Inc.
  • Pfizer Inc
  • Novartis AG
  • Thermo Fisher Scientific, Inc.
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Novo Nordisk A/S
  • Sanofi SA
  • Merck & Co., Inc.
  • Amgen Inc.
  • Bayer AG
  • Lonza Group
Product Code: SMRC23669

According to Stratistics MRC, the Global Monoclonal Antibodies Market is accounted for $230.6 billion in 2023 and is expected to reach $591.5 billion by 2030 growing at a CAGR of 14.4% during the forecast period. Monoclonal antibodies (mAbs) are a class of proteins with the capacity to attach to particular cell types. These are identical immunoglobulins that recognise a specific binding site on the antigen and were produced by a single B-cell. MAbs are being utilised more frequently for therapeutic and diagnostic purposes for various diseases because of their selectivity to distinct epitopes. Monoclonal antibodies are now widely used to treat a variety of conditions, including cancer, cardiovascular illness, autoimmune disorders, blood disorders, and infectious diseases.

According to the World Health Organization, in 2020, around 10 million people died due to cancer worldwide. This has proportionated one third deaths due to cancer in respective year.

Market Dynamics:

Driver:

  • Favourability for personalised medicine has increased.
  • The desire for personalised medicine is increasing as research and development of therapeutic antibodies has paved the way for targeted therapies because different people respond and behave differently to a given medication. Since monoclonal antibodies are used in cancer therapy, these treatments are less likely to cause adverse effects than traditional chemotherapy. The development of the market is anticipated to be aided by personalised cancer therapy and fewer adverse effects from monoclonal antibodies.

Restraint:

  • Stringent regulatory issues.
  • The market's expansion is hindered by strict regulatory requirements pertaining to drug approvals and drug testing. Additionally, a number of nations prohibit the testing of medicines on people before they have received the required authorisation. The ability of commercially available treatments to cure once-incurable diseases has paved the path for the introduction of ground-breaking drugs to the market. The market's expansion is hampered by the numerous regulatory compliances that are associated with these medications.

Opportunity:

  • Increase in the incidence of cancer.
  • One of the main factors influencing the market's growth rate is the rising incidence of cancer. Due to the rapidly expanding global market for monoclonal antibodies, monoclonal antibodies are increasingly being employed in the treatment of numerous tumours in industrialised nations. Rapid increases in the prevalence of rare and chronic infectious diseases, as well as the large number of monoclonal antibodies recommended for use in cancer treatment regimens, have provided the market with potential for revenue growth.

Threat:

  • High cost associated with monoclonal antibodies.
  • Monoclonal antibodies are still only employed in industrialised nations and not in emerging or poor nations due to the high cost of production. Such high drug costs can impede uptake and restrict access to medicines for sizable patient populations in poor nations. The high expenditures of the development and the subsequent price increase may limit market expansion.

COVID-19 Impact:

  • The pandemic had three main effects on the economy: it directly influenced drug demand and production, it disrupted distribution systems, and it had a financial impact on businesses and financial markets. The market for monoclonal antibodies has benefited from the impact since these antibodies work to prevent and treat early infections. Monoclonal antibodies are being used by numerous businesses in an effort to develop an effective vaccine for a novel corona virus disease. The researchers are assisted by government agencies by their approval of crises.
  • The cancer segment is expected to be the largest during the forecast period
  • The cancer segment is expected to be the largest during the forecast period, owing to increased prevalence of cancer. This expansion is simply ascribed to the increased demand for monoclonal antibodies in the treatment of various cancers. One of the main reasons why there is such a large demand for monoclonal antibodies among cancer patients is their increased effectiveness in the treatment of cancer with minimal or no adverse effects.
  • The hospital pharmacy segment is expected to have the highest CAGR during the forecast period
  • The hospital pharmacy segment is expected to have the highest CAGR during the forecast period. This is due to a rise in hospital admissions brought on by the rising prevalence of a number of chronic diseases like cancer, autoimmune disorders, and rheumatoid arthritis. The market income of hospital pharmacy has increased as a result of greater access to modern healthcare services. These pharmacies are an easy way to purchase a variety of medications due to the large variety of products and drugs they carry.

Region with largest share:

North America is projected to hold the largest market share during the forecast period, owing to the strong presence of key business players and number of product approvals. Demand for monoclonal antibodies in the local market is driven by increased product acceptance for efficient disease treatment. In addition, rising R&D spending by businesses and government funding for cancer research have facilitated the development of innovative monoclonal antibody treatments.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period, due to the increasing disposable income and rising focus on healthcare. The main causes that are anticipated to increase the prevalence of cancer and other chronic diseases in the population are the rising consumption of processed foods, rising smoking rates, and rising tobacco use. Additionally, the growing elderly population will have a favourable effect on sales in the near future.

Key players in the market:

Some of the key players in Monoclonal Antibodies market include: Johnson & Johnson Services, Inc., Viatris Inc., Abbott Laboratories, Eli Lilly And Company, Bristol-Myers Squibb, Biogen Inc., Merck & Co., Inc., Pfizer Inc, Novartis AG, Thermo Fisher Scientific, Inc., AstraZeneca plc, GlaxoSmithKline plc, Novo Nordisk A/S, Sanofi S.A., Merck & Co., Inc., Amgen Inc., Bayer AG and Lonza Group.

Key Developments:

  • In March 2022, Sanofi S.A. and Blackstone Life Sciences entered a collaboration for accelerating the development of a subcutaneous formulation of Sarclisa mAb for the treatment of patients with multiple myeloma.
  • In February 2022, Bebtelovimab is an antibody that can reduce the effects of Omicron variant. Eli Lilly and Company announced that the Food and Drug Administration (FDA) of the United States had given bebtelovimab an Emergency Use Authorization (EUA).
  • In January 2022, Lonza and HaemaLogiX Ltd. (HaemaLogiX) made a deal for Lonza to make the next clinical batch (cGMP) of KappaMab, HaemaLogiX's most important treatment candidate for multiple myeloma.

Source types Covered:

  • Humanized
  • Chimeric
  • Murine
  • Human
  • Other Source Types

Production Types Covered:

  • In Vitro
  • In Vivo

Route of Administration Covered:

  • Intravitreal
  • Subcutaneous
  • Intravenous

Distribution Channels Covered:

  • Navy
  • Airforce
  • Army
  • Other End Users

Applications Covered:

  • Online Pharmacy
  • Hospital Pharmacy
  • Retail Pharmacy

End Users Covered:

  • Specialty Centers
  • Hospitals
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Monoclonal Antibodies Market, By Source Type

  • 5.1 Introduction
  • 5.2 Humanized
  • 5.3 Chimeric
  • 5.4 Murine
  • 5.5 Human
  • 5.6 Other Source Types

6 Global Monoclonal Antibodies Market, By Production Type

  • 6.1 Introduction
  • 6.2 In Vitro
  • 6.3 In Vivo

7 Global Monoclonal Antibodies Market, By Indication

  • 7.1 Introduction
  • 7.2 Infectious Diseases
  • 7.3 Inflammatory Diseases
  • 7.4 Cancer
    • 7.4.1 Lung cancer
    • 7.4.2 Colorectal cancer
    • 7.4.3 Ovarian cancer
    • 7.4.4 Breast cancer
  • 7.5 Autoimmune Diseases
  • 7.6 Other Indications

8 Global Monoclonal Antibodies Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Intravitreal
  • 8.3 Subcutaneous
  • 8.4 Intravenous

9 Global Monoclonal Antibodies Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Online Pharmacy
  • 9.3 Hospital Pharmacy
  • 9.4 Retail Pharmacy

10 Global Monoclonal Antibodies Market, By Application

  • 10.1 Introduction
  • 10.2 Infectious Diseases
  • 10.3 Neurological Diseases
  • 10.4 Autoimmune Diseases
  • 10.5 Oncology
  • 10.6 Other Applications

11 Global Monoclonal Antibodies Market, By End User

  • 11.1 Introduction
  • 11.2 Specialty Centers
  • 11.3 Hospitals
  • 11.4 Research Institutes
  • 11.5 Other End Users

12 Global Monoclonal Antibodies Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Johnson & Johnson Services, Inc.
  • 14.2 Viatris Inc.
  • 14.3 Abbott Laboratories
  • 14.4 Eli Lilly And Company
  • 14.5 Bristol-Myers Squibb
  • 14.6 Biogen Inc.
  • 14.7 Merck & Co., Inc.
  • 14.8 Pfizer Inc
  • 14.9 Novartis AG
  • 14.10 Thermo Fisher Scientific, Inc.
  • 14.11 AstraZeneca plc
  • 14.12 GlaxoSmithKline plc
  • 14.13 Novo Nordisk A/S
  • 14.14 Sanofi S.A.
  • 14.15 Merck & Co., Inc.
  • 14.16 Amgen Inc.
  • 14.17 Bayer AG
  • 14.18 Lonza Group

List of Tables

  • Table 1 Global Monoclonal Antibodies Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Monoclonal Antibodies Market Outlook, By Source Type (2021-2030) ($MN)
  • Table 3 Global Monoclonal Antibodies Market Outlook, By Humanized (2021-2030) ($MN)
  • Table 4 Global Monoclonal Antibodies Market Outlook, By Chimeric (2021-2030) ($MN)
  • Table 5 Global Monoclonal Antibodies Market Outlook, By Murine (2021-2030) ($MN)
  • Table 6 Global Monoclonal Antibodies Market Outlook, By Human (2021-2030) ($MN)
  • Table 7 Global Monoclonal Antibodies Market Outlook, By Other Source Types (2021-2030) ($MN)
  • Table 8 Global Monoclonal Antibodies Market Outlook, By Production Type (2021-2030) ($MN)
  • Table 9 Global Monoclonal Antibodies Market Outlook, By In Vitro (2021-2030) ($MN)
  • Table 10 Global Monoclonal Antibodies Market Outlook, By In Vivo (2021-2030) ($MN)
  • Table 11 Global Monoclonal Antibodies Market Outlook, By Indication (2021-2030) ($MN)
  • Table 12 Global Monoclonal Antibodies Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 13 Global Monoclonal Antibodies Market Outlook, By Inflammatory Diseases (2021-2030) ($MN)
  • Table 14 Global Monoclonal Antibodies Market Outlook, By Cancer (2021-2030) ($MN)
  • Table 15 Global Monoclonal Antibodies Market Outlook, By Lung cancer (2021-2030) ($MN)
  • Table 16 Global Monoclonal Antibodies Market Outlook, By Colorectal cancer (2021-2030) ($MN)
  • Table 17 Global Monoclonal Antibodies Market Outlook, By Ovarian cancer (2021-2030) ($MN)
  • Table 18 Global Monoclonal Antibodies Market Outlook, By Breast cancer (2021-2030) ($MN)
  • Table 19 Global Monoclonal Antibodies Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 20 Global Monoclonal Antibodies Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 21 Global Monoclonal Antibodies Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 22 Global Monoclonal Antibodies Market Outlook, By Intravitreal (2021-2030) ($MN)
  • Table 23 Global Monoclonal Antibodies Market Outlook, By Subcutaneous (2021-2030) ($MN)
  • Table 24 Global Monoclonal Antibodies Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 25 Global Monoclonal Antibodies Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 26 Global Monoclonal Antibodies Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 27 Global Monoclonal Antibodies Market Outlook, By Hospital Pharmacy (2021-2030) ($MN)
  • Table 28 Global Monoclonal Antibodies Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 29 Global Monoclonal Antibodies Market Outlook, By Application (2021-2030) ($MN)
  • Table 30 Global Monoclonal Antibodies Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 31 Global Monoclonal Antibodies Market Outlook, By Neurological Diseases (2021-2030) ($MN)
  • Table 32 Global Monoclonal Antibodies Market Outlook, By Autoimmune Diseases (2021-2030) ($MN)
  • Table 33 Global Monoclonal Antibodies Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 34 Global Monoclonal Antibodies Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 35 Global Monoclonal Antibodies Market Outlook, By End User (2021-2030) ($MN)
  • Table 36 Global Monoclonal Antibodies Market Outlook, By Specialty Centers (2021-2030) ($MN)
  • Table 37 Global Monoclonal Antibodies Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 38 Global Monoclonal Antibodies Market Outlook, By Research Institutes (2021-2030) ($MN)
  • Table 39 Global Monoclonal Antibodies Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.